NEW YORK, March 10, 2017 -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of Gigamon Inc. securities (NYSE:GIMO) from October 27, 2016 through January 17, 2017, inclusive (the “Class Period”) of the important March 28, 2017 lead plaintiff deadline in the class action. The lawsuit seeks to recover damages for Gigamon investors under the federal securities laws.
To join the Gigamon class action, go to http://rosenlegal.com/cases-1041.html or call Phillip Kim, Esq. or Kevin Chan, Esq. toll-free at 866-767-3653 or email [email protected] or [email protected] for information on the class action.
NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. YOU MAY RETAIN COUNSEL OF YOUR CHOICE.
According to the lawsuit, throughout the Class Period Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about Gigamon’s business, operations, and prospects, including that: (1) Gigamon was experiencing reduced product bookings in its North America West region; (2) several of Gigamon’s significant customers were deferring purchasing decisions into 2017; (3) Gigamon failed to properly include these trends in its financial guidance; and (4) as a result, Defendants’ statements about Gigamon’s business, operations, and prospects, including statements about its revenue guidance, were false and misleading and/or lacked a reasonable basis. When the true details entered the market, the lawsuit claims that investors suffered damages.
A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than March 28, 2017. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, go to http://rosenlegal.com/cases-1041.html or to discuss your rights or interests regarding this class action, please contact Phillip Kim, Esq. or Kevin Chan, Esq. of Rosen Law Firm toll free at 866-767-3653 or via e-mail at [email protected] or [email protected].
Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm.
Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Attorney Advertising. Prior results do not guarantee a similar outcome.
Contact Information: Laurence Rosen, Esq. Phillip Kim, Esq. Kevin Chan, Esq. The Rosen Law Firm, P.A. 275 Madison Avenue, 34th Floor New York, NY 10016 Tel: (212) 686-1060 Toll Free: (866) 767-3653 Fax: (212) 202-3827 [email protected] [email protected] [email protected] www.rosenlegal.com


Starlink Plans Satellite Orbit Reconfiguration in 2026 to Boost Space Safety
Applied Digital Stock Rises on AI Cloud Spinoff Plan and ChronoScale Launch
Bain Capital Moves to Acquire Majority Stake in Echo Marketing
Lockheed Martin Secures $328.5 Million U.S. Defense Contract for Advanced Systems Supporting Taiwan Air Force
Air China Orders 60 Airbus A320neo Jets in $9.5 Billion Deal as Airbus Strengthens Grip on China Market
Nike Stock Rises After CEO Elliott Hill Buys $1 Million in Shares
Elon Musk’s xAI Expands Supercomputer Infrastructure With Third Data Center to Boost AI Training Power
Royalty Pharma Stock Rises After Acquiring Full Evrysdi Royalty Rights from PTC Therapeutics
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China, Boosting Access to Wegovy and Mounjaro
Citigroup to Exit Russia With Sale of AO Citibank to Renaissance Capital
Vanda Pharmaceuticals Wins FDA Approval for New Motion Sickness Drug After Four Decades
Anghami Stock Soars After Strong H1 2025 Results, Revenue Nearly Doubles on OSN+ Integration
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China as Competition Intensifies
Australia’s Modern Gold Rush: Hobby Prospectors Flock to Victoria’s Golden Triangle
Neuralink Plans High-Volume Brain Implant Production and Fully Automated Surgery by 2026
Baidu Shares Surge as Company Plans Kunlunxin AI Chip Spin-Off and Hong Kong Listing
Target Stock Rallies as Activist Interest Sparks Hopes for Strategic Change 



